COMMUNIQUÉS West-GlobeNewswire

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
31/05/2024
Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation Paris and Tarrytown, NY May 31, 2024 . The US Food and Drug Administration (FDA) has extended by three months the [...]
Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2
31/05/2024
Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2 Paris et Tarrytown (New York), le 31 mai 2024 . La Food and Drug Administration (FDA) [...]
CloudMD Reports First Quarter 2024 Results
31/05/2024
First Quarter Highlights Q1 Revenue of $22.8 million compared to $22.6 million in Q4 2023 and $22.9 million in the prior year. Q1 2024 gross profit margin of 37.0% increased from 36.9% in the prior year. Q1 Adjusted [...]
Syncromune, Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer
31/05/2024
SYNC-T SV-102 Therapy combines partial tumor oncolysis with a fixed-dose combination multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic castrate-resistant [...]
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
31/05/2024
TLX591 is an investigational anti-PSMA 1 radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen. Reported median radiographic [...]
Hydreight Reports Record Topline(1) Revenue of $4.87M in Q1-2024 (YOY Increase of 33%)
31/05/2024
“We had an outstanding quarter with record revenue...Our focus in 2024 is to continue growing revenue, becoming a profitable company and introducing our story to more potential shareholders” - Shane Madden, CEO of [...]
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
31/05/2024
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
31/05/2024
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52) 1 Remibrutinib, an oral Bruton’s tyrosine kinase [...]
Goodness Growth Holdings to Complete Non-Brokered Private Placement to Support the Relocation of a Minnesota Dispensary
31/05/2024
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and [...]
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
30/05/2024
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx ® [...]
Rakovina Therapeutics Announces 2024 Q1 Financial Results and Provides Corporate Update
30/05/2024
All dollar amounts reflected in Canadian dollars unless otherwise stated VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX.V: RKV), (the “Company”) a biopharmaceutical company [...]
Sotera Health Announces Closing of $1.5 Billion Term Loan B and $750 Million Senior Secured Note Financings
30/05/2024
CLEVELAND, May 30, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and [...]
Noah Medical and CEO Dr. Jian Zhang Named Finalists in Surgical Robotics Technology (SRT) Industry Awards
30/05/2024
Next-generation robotics company and its CEO recognized separately for pioneering work, innovative new technology, and rapid progress SAN CARLOS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah [...]
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
30/05/2024
SOD1 -ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe 1 QALSODY is Biogen’s third rare disease therapy to be approved in the EU, [...]
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
30/05/2024
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies [...]
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
30/05/2024
Late-breaking presentation of data at American Transplant Congress on Monday, June 3 Data show potential to monitor for therapeutic efficacy and recurrence Potential repeat testing opportunities with claims expansion [...]
SAB Biotherapeutics Announces Departure of Chief Financial Officer
30/05/2024
MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte [...]
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
30/05/2024
L eiden , the Netherlands, May 30, 2024 : Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing Authorisation [...]
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
30/05/2024
Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ≥20 Conference call on Tuesday, June 4, at 4:15 p.m. ET NEW YORK and VIENNA [...]

Pages